- Detailed report to come : Phagoburn outcomes will be presented in a report to be added soon on this website.
Phagoburn Clinical Trial
Within Phagoburn, a phase I/II clinical study aiming at assessing the safety, effectiveness and pharmacodynamics of two therapeutic phage cocktails to treat either E. coli or P. aeruginosa burn wound infections is currently being implemented.
This clinical study was launched in July 2015. It is the first international clinical study on phages in the world that meets international standards in clinical evaluation. It takes place simultaneously in France, Belgium and Switzerland, in different burn wound treatment centres acting as clinical centres. It will involve 220 patients.
Pherecydes Pharma is the sponsor of the trial, which is coordinated by Percy military hospital (Principal Investigator).
To find more about this clinical trial, you can also read about: